Tetrabenazine

Inke (API manufacturer) part of Neuraxpharm, provides wide range of APIs which includes Prasugrel base. Indication: Prophylaxis and therapy of thrombosis

EU DMF

Inke (API manufacturer) part of  Neuraxpharm, provides wide range of APIs which includes Quetiapine hemifumarate. Indication: Schizophrenia, psychosis

JP and KR DMF

Inke (API manufacturer) part of  Neuraxpharm, provides wide range of APIs which includes Revefenacin for COPD treatment

Inke (API manufacturer) part of  Neuraxpharm, provides wide range of APIs which includes Risperidone (sterile). Indication: Schizophrenia, psychosis

CEP and US-KR DMF

Inke (API manufacturer) part of  Neuraxpharm, provides wide range of APIs which includes Rivaroxaban. Indication: Thrombosis. Stroke

DMF available

Inke (API manufacturer) part of  Neuraxpharm, provides wide range of APIs which includes Salmeterol xinafoate. Indication Asthma and COPD

CEP/ US-CN-KR DMF

Inke (API manufacturer) part of  Neuraxpharm, provides wide range of APIs which includes Tiotropium Bromide for COP

CEP and US-CN DMF

Inke (API manufacturer) part of  Neuraxpharm, provides wide range of APIs which includes Umeclidinium for COPD 

Inke (API manufacturer) part of  Neuraxpharm, provides wide range of APIs which includes Vilanterol Trifenatate for Asthma and COPD 

Inke (API manufacturer) part of  Neuraxpharm, provides wide range of APIs which includes Zolmitriptan. Indication: Migraine

EU-US DMF

ARFORMOTEROL, FORMOTEROL, GLYCOPYRROLATE,  INDACATEROL, OLODATEROL SALMETEROL, TIOTROPIUM, UMECLIDINIUM and VILANTEROL

More than twenty years’ experience in micronisation.  Inke is able to provide solutions for early market entry opportunities or for products requiring in-depth knowledge of micronisation techniques.
Our experience in in-house micronisation technology at Inke means we can provide:

...

Complete overview of Inke’s API product portfolio and development pipeline, covering Inhalation, CNS, Ophthalmic HPAPIs and Specialty APIs. The document includes product indications, micronisation availability, regulatory status (CEPs and DMFs), and development stage information for pipeline products.